Clario
Generated by Meeveem AI
"Endpoint technology solutions that generate the richest clinical evidence for drug trials"
About Clario
Clario provides endpoint technology and services for pharmaceutical and biotechnology clinical trials. Its platforms cover cardiac safety, electronic clinical outcome assessments, medical imaging, precision motion and respiratory measurements. Scientific and regulatory specialists work with software, connected devices and artificial intelligence to generate evidence for site-based, hybrid and decentralised studies.
Based in Philadelphia, Clario traces its clinical evidence work to 1972; ERT and Bioclinica merged under the Clario name in 2021. Its experience spans over 30,000 trials in more than 100 countries, with translations in over 100 languages and round-the-clock partner and patient support. Clario became part of Thermo Fisher Scientific in March 2026.
Learning and career development
Clario’s Leadership Academy and Corporate Mentoring Programme are open to all employees. Development resources include monthly podcasts, Brown Bag seminars and more than 40 courses covering skills such as communication and conflict resolution. Its careers pages also describe on-the-job learning and tuition assistance.
3900
Team Members
1972
Founded
Digital Health
Sector
Hybrid
Work Environment